Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer

Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian

This is a randomized, open-label, two-arm study in patients with relapsed epithelial ovarian tumors. Patients will be randomized in a 1:1 ratio to receive olaparib or standard chemotherapy with the possibility of crossover at the time of progression.

Inclusion Criteria:

• with recurrent epithelial carcinoma of the ovary, fallopian tube or primary peritoneum
• At least 1 previous line of chemotherapy
• Measurable disease
• Patients have a normal organ and bone marrow function measured within 28 days of randomization
• WHO 0-2

Exclusion Criteria:

• Primary platinum-refractory disease
• Known hypersensitivity to olaparib
• Resting ECG with QTc > 470 msec
• Concomitant use of known potent CYP3A4 inhibitors
• Symptomatic uncontrolled brain metastases
• Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication